ATYR1940 in early onset FSHD

Phase 2, open-label, single-arm trial of Resolaris in facioscapulohumeral muscular dystrophy (FSHD), sponsored by aTyr Pharma. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events at 25 weeks, Number of Participants With a Clinical Laboratory Abnormality Leading to an AE at 25 weeks and 3 more. Started Mar 2016; status: completed.